1-12 of 12
Keywords: Therapy
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Int Arch Allergy Immunol (2020) 181 (10): 746–753.
Published Online: 03 November 2020
...), after 1 month (T1), and 6 months of therapy were collected in a database. Results: All treated patients showed an increase in the percentage of forced expiratory volume in the first second (FEV1) and FEV1/forced vital capacity ratio and a decrease of peripheral eosinophils for both drugs after 1 month...
Journal Articles
Int Arch Allergy Immunol (2020) 181 (11): 822–830.
Published Online: 12 August 2020
... a significant beneficial effect of THC in mice with allergic asthma. Glucocorticosteroids (GCs) are commonly used drugs in asthma. Whether THC supplementation could promote the beneficial effects of GC therapy on asthma has not yet been reported. The current study aimed to investigate the combined efficacy...
Journal Articles
Int Arch Allergy Immunol (2020) 181 (8): 606–612.
Published Online: 09 June 2020
... oxide, and validated questionnaires. Results: A significant reduction in asthma exacerbations was observed in all patients after 6 months of the biological therapy ( p = 0.0009), and 4/6 patients discontinued chronic oral steroids. A significant improvement in ACT, FEV1, SNOT22, and alveolar nitric...
Journal Articles
Int Arch Allergy Immunol (2018) 176 (2): 157–162.
Published Online: 07 May 2018
... with a diagnosis of allergic rhinitis and dry eye were included. Symptoms and findings of patients before and after nasal steroid therapy were compared. Result: Ocular Surface Disease Index scores for dry eye symptoms showed significant improvement after nasal steroid treatment ( p = 0.003). In the Schirmer test...
Journal Articles
Journal Articles
Journal Articles
Int Arch Allergy Immunol (2012) 158 (1): 43–53.
Published Online: 29 December 2011
.... However, neither short-term nor long-term treatment significantly reduced plasma cell numbers, anti-OVA IgG1 serum titers or allergic airway inflammation or ablated airway hyperresponsiveness. Conclusion: Our results suggest that bortezomib treatment has only limited value as plasma cell-depleting therapy...
Journal Articles
Journal Articles
Int Arch Allergy Immunol (1993) 100 (2): 93–98.
Published Online: 02 September 2009
... obtained to date are described. HIV-1 AIDS vaccine Therapy GP160 Clinical trial © 1993 S. Karger AG, Basel 1993 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form...
Journal Articles
Journal Articles
Int Arch Allergy Immunol (2003) 130 (4): 247–257.
Published Online: 09 May 2003
... complement and the virus is illuminated for the three different stages of HIV pathogenesis and for events during therapy: (1) the acute infection process with the early events in mucosa and serum; (2) the asymptomatic stage with the complex interplay between complement-induced lysis and viral evasion...
Journal Articles
Int Arch Allergy Immunol (2002) 127 (2): 156–159.
Published Online: 28 March 2002
...Klaus Wolff Therapy of cutaneous mastocytosis is directed towards skin and systemic symptoms due to mediator release and targeted on skin lesions. Symptomatic therapy of cutaneous mastocytosis involves agents that inhibit the release of mediators or antagonize H1 and H2 receptors...